Trending...
- Los Angeles County to Begin Distributing Vote by Mail Ballots to Registered Voters in Long Beach Beginning April 30 - 267
- For Small Business Week: This Math should be Required Reading For Every Business in the Universe!
- Emmy Winning Broadcaster Dave Benz Launches TixScape to Help Fans Find World Cup Deals
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012, its next-generation iStent inject® device in the United States in September 2018 and most recently, its iStent injectW device in the United States in October 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
More on The Californer
- LA Lemon Lawyer Explains the Number of Repairs Required to Qualify Under California Lemon Law
- New Linux Blog LinuxDork.com Launches With Practical Guides for Self-Hosters and Tinkerers
- Bay Area Housing Market Shifts as "Must-Move" Buyers Replace Traditional Demand
- Governor Newsom honors California's fallen peace officer heroes
- Michael H. Kaplan, Colorado Workers' Compensation Attorney, Rallies Athlete Unions Against Proposed Legislative "Carve-Outs"
Filed Under: Business
0 Comments
Latest on The Californer
- May the 4th be with you: California reaches for the stars with space accomplishments that are out of this world
- Fulton County DA Fani Willis Officially Endorses Dr. Heavenly Kimes + Black Economic Agenda
- UVIFY to Debut New Product Line at XPONENTIAL 2026 in Detroit
- West Coast Sourdough Acts to Protect Business Interests and Contractual Integrity
- Lawyers Realty Group Opens New Practice for Home Equity Investment Disputes
- Bellwether Farm Presents Kerry Hill Lamb to His Majesty King Charles III During Historic U.S. State Visit
- New Study Finds Americans Judge Vacations on Value, Not Price — Signaling a Permanent Shift in How Travel Gets Booked
- Della, aka Shardella, Princess of Atlas Elite Entertainment gets award
- Countrywide Rental Strengthens Worksite Organization in Beatrice, Alabama
- Pomona Organic Launches New Website, Surpasses 10 Million Bottles Sold, and Opens Affiliate Program to Creators
- Looking for the best way to Take the Guesswork out of your Advertising? Start with this math!
- Postmortem Pathology Opens Sacramento Office Offering Private Autopsies for Families and Healthcare Investigations
- Postmortem Pathology, a leading provider of private autopsies, has announced its expansion into the Las Vegas market
- Coast to Coast for America's 250th — Rally4Vets Joins Face the Fight Coalition
- LA Lemon Lawyer Reveals How Much is a Lemon Law Settlement in Los Angeles
- Kick'em Out Quick® Evictions Announces a New Endorsed Eviction Attorney in Atlanta / Fulton County, GA
- Summer Jewellery Trends 2026: The Pieces Defining Effortless Statement Luxury
- Cardiac Stroke Post Treatment , Therapies, Dr.Abhay Kumar Pati, Physician, Author, Hayward, CA USA
- The Art of Intentional Gifting: Why She Deserves More Than Just a "Mass-Market" Box
- Unikoo Group Offers Factory-Direct Frameless Shower Doors With Free Nationwide Shipping